Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Other Non-Current Assets (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Other Non-Current Assets data on record, last reported at $8.2 million in Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 7.92% year-over-year to $8.2 million; the TTM value through Sep 2025 reached $8.2 million, up 7.92%, while the annual FY2024 figure was $7.8 million, 179.24% up from the prior year.
  • Other Non-Current Assets reached $8.2 million in Q3 2025 per COEP's latest filing, down from $8.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $8.8 million in Q1 2025 and bottomed at $348333.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $4.9 million, with a median of $3.7 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: tumbled 92.38% in 2022, then skyrocketed 706.72% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $4.6 million in 2021, then crashed by 92.38% to $348333.0 in 2022, then surged by 706.72% to $2.8 million in 2023, then skyrocketed by 179.24% to $7.8 million in 2024, then increased by 4.25% to $8.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $8.2 million in Q3 2025, $8.5 million in Q2 2025, and $8.8 million in Q1 2025.